Company Active LTD

Company profile

Diagnostig Ltd

Diagnostig Ltd is a UK company with status active founded in 2012 based in Wales.

CRN
07975264
Founded
2012
Age
14

Overview

Legal name
DIAGNOSTIG LTD
Region
Wales
Registered address
MSPARC
GAERWYN
YNYS MON
WALES
LL60 6AG
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

6 events
19 Mar
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

05 Mar
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

05 Nov
2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQ0MjAxNDE3NmFkaXF6a2N4

Published 05 Nov 2024 09:45

05 Mar
2012

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2015
Funded years
2015, 2016, 2018, 2025, 2026
Age at first award
3 years

Projects

2026 Collaborative R&D Lead participant

HERALD: Revolutionizing Livestock Disease Detection Through Advanced Diagnostics

1 Apr 2026 to 31 Mar 2027

Awarded
£93,790
Total cost £133,985

**HERALD (Health Enhancement through Rapid Assessment of Livestock Diseases)** is a collaborative project delivering fast, practical diagnostics for Johne's disease (JD) in cattle, with limited feasibility work preparing the platform for future bovine tuberculosis applications. JD is widespread and costly for dairy and beef producers, undermining animal w...

2025 Grant for R&D Lead participant

Evaluation of an innovative assay for Johne's disease using North Wales herds

1 Apr 2025 to 31 Mar 2026

Awarded
£83,000
Total cost £83,000

Although bovine TB in cattle has a very high profile, it is much less widespread than another disease caused by a mycobacterium, Johne's disease. Johne's, caused by _Mycobacterium avium_ paratuberculosis, is an infectious wasting disease which develops very slowly but statistically is present in around 70 % of herds (albeit perhaps in very few animals). T...

2018 Collaborative R&D Lead participant

Proof of concept for a rapid diagnosis of infection with non-tuberculous mycobacteria in immune compromised patients

1 Dec 2018 to 30 Nov 2019

Awarded
£36,817
Total cost £52,595

"Although infection with _Mycobacterium tuberculosis_, the cause of TB, is very widely studied, non-tuberculous mycobacteria (NTMs) are much more common in the environment but generally do not present any human health problems. However, they are a significant problem in patients whose immune systems are compromised. Thus, up to 10-20 % of cystic fibrosis ...

2016 GRD Proof of Concept Lead participant

A new approach to point of assessment diagnosis of tuberculosis

1 Mar 2016 to 28 Feb 2017

Awarded
£60,000
Total cost £100,000

Tuberculosis remains one of the most significant causes of death, particularly in individuals co-infected with HIV-AIDS; co-infection can lead to a life expectancy of a few weeks and has, for example, reduced life expectancy in South Africa by around 10 years. Although there are many methods that are supposed to detect the disease, in practice none of the...

2015 GRD Proof of Market Lead participant

A new approach to point of assessment diagnosis of tuberculosis

1 Jun 2015 to 31 Aug 2015

Awarded
£15,000
Total cost £25,000

We have developed a novel device for the detection of TB which works in under 30 minutes; this is based on the recognition of unique molecules identical to components of the cell walls of mycobacteria by antibodies present in the serum of individuals with active TB. The target set by the World Health Organisation is for a field device that works rapidly a...

Product types

Collaborative R&D Grant for R&D GRD Proof of Concept GRD Proof of Market